VRTX

Vertex Pharmaceuticals
D

VRTX

472.42
USD
3.66
(0.78%)
مغلق
حجم التداول
27,542
الربح لكل سهم
18
العائد الربحي
-
P/E
-123
حجم السوق
121,316,127,083
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 10 أشهر
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
-0.860
(-0.45%)
191.460 USD
AMGN
AMGN
1.69
(0.57%)
296.87 USD
BIIB
BIIB
-1.060
(-0.79%)
133.110 USD
BMRN
BMRN
0.135
(0.23%)
58.240 USD
GILD
GILD
2.467
(2.25%)
112.100 USD
INCY
INCY
1.400
(2.04%)
69.990 USD
LLY
LLY
6.37
(0.80%)
799.15 USD
REGN
REGN
2.95
(0.52%)
570.78 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.